Tuesday, March 18, 2025
spot_img

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., March 17, 2025 (GLOBE NEWSWIRE) — Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on March 12, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).

The new non-executive employee received an option to purchase 35,000 shares of Annexon common stock. The option carries a ten-year term and an exercise price per share equal to $2.60, which was the closing price of Annexon’s common stock on March 14, 2025, the date of grant, and vests over 4 years, with 25% of the shares underlying the options vesting on the first anniversary of the grant date and an additional 1/48th of the shares vesting monthly thereafter, subject to continued service through the applicable vesting dates.

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is developing therapeutics that stop classical complement-driven neurodegeneration as first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of classical complement’s potent inflammatory pathway that when misdirected can lead to tissue damage and loss. By targeting C1q, our immunotherapies are designed to stop this neuroinflammatory cascade in disease before it starts. Our pipeline spans three diverse therapeutic areas – autoimmune, neurodegenerative and ophthalmic diseases – and includes targeted investigational drug candidates designed to address the unmet needs of over 8 million people worldwide. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.

Investor Contact:

Joyce Allaire
LifeSci Advisors
[email protected]

Powered by SlickText.com

Hot this week

Alliance Witan PLC – Transaction In Own Shares

 Alliance Witan PLCLEI: 213800SZZD4E2IOZ9W55  TRANSACTION IN OWN SHARES  Alliance Witan...

The recording of Šiaulių Bankas Investor Conference Webinar on Rebranding

During the Investor Conference Webinar Vytautas Sinius, CEO and...

Middlefield Canadian Income PCC: Net Asset Value(s)

Middlefield Canadian Income PCC Net Asset Value ...

Ignitis Group addresses public discussions on offshore wind development

AB “Ignitis grupė” (hereinafter – the Group), in response...

Topics

Alliance Witan PLC – Transaction In Own Shares

 Alliance Witan PLCLEI: 213800SZZD4E2IOZ9W55  TRANSACTION IN OWN SHARES  Alliance Witan...

The recording of Šiaulių Bankas Investor Conference Webinar on Rebranding

During the Investor Conference Webinar Vytautas Sinius, CEO and...

Middlefield Canadian Income PCC: Net Asset Value(s)

Middlefield Canadian Income PCC Net Asset Value ...

Ignitis Group addresses public discussions on offshore wind development

AB “Ignitis grupė” (hereinafter – the Group), in response...

The results of business activity of ŽEMAITIJOS PIENAS, AB group in 2024, excluding audit

In 2024, consolidated turnover (excluding audit) of ŽEMAITIJOS PIENAS,...

Ignitis Group addresses public discussions on offshore wind development

AB “Ignitis grupė” (hereinafter – the Group), in response...
spot_img

Related Articles

Popular Categories

spot_img